RU2665021C2 - Способы и композиции для улучшения когнитивных функций - Google Patents

Способы и композиции для улучшения когнитивных функций Download PDF

Info

Publication number
RU2665021C2
RU2665021C2 RU2013141155A RU2013141155A RU2665021C2 RU 2665021 C2 RU2665021 C2 RU 2665021C2 RU 2013141155 A RU2013141155 A RU 2013141155A RU 2013141155 A RU2013141155 A RU 2013141155A RU 2665021 C2 RU2665021 C2 RU 2665021C2
Authority
RU
Russia
Prior art keywords
oxo
cognitive impairment
methyl
hydrogen atom
butanamide
Prior art date
Application number
RU2013141155A
Other languages
English (en)
Russian (ru)
Other versions
RU2013141155A (ru
Inventor
Михела Галлахер
Ребекка Хаберман
Мин Тен Кох
Original Assignee
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Джонс Хопкинс Юниверсити filed Critical Дзе Джонс Хопкинс Юниверсити
Publication of RU2013141155A publication Critical patent/RU2013141155A/ru
Application granted granted Critical
Publication of RU2665021C2 publication Critical patent/RU2665021C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
RU2013141155A 2011-02-09 2012-02-09 Способы и композиции для улучшения когнитивных функций RU2665021C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441251P 2011-02-09 2011-02-09
US61/441,251 2011-02-09
PCT/US2012/024556 WO2012109491A1 (en) 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018129580A Division RU2792010C2 (ru) 2011-02-09 2012-02-09 Способы и композиции для улучшения когнитивных функций

Publications (2)

Publication Number Publication Date
RU2013141155A RU2013141155A (ru) 2015-03-20
RU2665021C2 true RU2665021C2 (ru) 2018-08-24

Family

ID=46638963

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013141155A RU2665021C2 (ru) 2011-02-09 2012-02-09 Способы и композиции для улучшения когнитивных функций

Country Status (9)

Country Link
US (2) US20120214859A1 (enExample)
EP (2) EP2672822A4 (enExample)
JP (7) JP2014505108A (enExample)
CN (2) CN103476255A (enExample)
AU (6) AU2012214303A1 (enExample)
BR (1) BR112013020283A2 (enExample)
CA (1) CA2826765C (enExample)
RU (1) RU2665021C2 (enExample)
WO (1) WO2012109491A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
WO2014144546A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
EA034167B8 (ru) * 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN112569216B (zh) * 2019-09-30 2022-02-15 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
US20250213727A1 (en) 2022-03-25 2025-07-03 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN115517682B (zh) * 2022-11-25 2023-01-31 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2291860C2 (ru) * 2000-02-23 2007-01-20 ЮСиБи, С.А. Производные 2-оксо-1-пирролидина, способ их получения и применения
US20080167291A1 (en) * 2006-05-09 2008-07-10 Braincells, Inc. Neurogenesis by modulating angiotensin
EA200802380A1 (ru) * 2006-06-08 2009-06-30 Юсб Фарма, С.А. Совместные кристаллы пирролидинонов
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
US20100048634A1 (en) * 2005-04-20 2010-02-25 Albert Cha Method for treating apathy syndrome
US20100099735A1 (en) * 2008-10-16 2010-04-22 Michela Gallagher Methods and compositions for improving cognitive function

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ZA200508306B (en) * 2003-05-23 2007-03-28 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
PL1909764T3 (pl) * 2005-07-26 2015-03-31 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CN101647789B (zh) * 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US10806717B2 (en) * 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2291860C2 (ru) * 2000-02-23 2007-01-20 ЮСиБи, С.А. Производные 2-оксо-1-пирролидина, способ их получения и применения
US20100048634A1 (en) * 2005-04-20 2010-02-25 Albert Cha Method for treating apathy syndrome
US20080167291A1 (en) * 2006-05-09 2008-07-10 Braincells, Inc. Neurogenesis by modulating angiotensin
EA200802380A1 (ru) * 2006-06-08 2009-06-30 Юсб Фарма, С.А. Совместные кристаллы пирролидинонов
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
US20100099735A1 (en) * 2008-10-16 2010-04-22 Michela Gallagher Methods and compositions for improving cognitive function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
USERY JB et al. "A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures". J Neurooncol. 2010 Sep;99(2):251-60, , найдено 28.10.2015 из PubMed PMID: 20146087. *
USERY JB et al. "A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures". J Neurooncol. 2010 Sep;99(2):251-60, реферат, найдено 28.10.2015 из PubMed PMID: 20146087. *

Also Published As

Publication number Publication date
AU2016202670A1 (en) 2016-05-19
US20120214859A1 (en) 2012-08-23
CN103476255A (zh) 2013-12-25
RU2013141155A (ru) 2015-03-20
AU2021200325B2 (en) 2022-07-28
JP2025109773A (ja) 2025-07-25
EP2672822A4 (en) 2014-08-27
CA2826765A1 (en) 2012-08-16
EP2672822A1 (en) 2013-12-18
BR112013020283A2 (pt) 2016-07-19
AU2019268069A1 (en) 2019-12-12
AU2012214303A1 (en) 2013-09-12
RU2018129580A3 (enExample) 2022-03-25
JP2018100305A (ja) 2018-06-28
EP3400934A1 (en) 2018-11-14
CN109662961A (zh) 2019-04-23
JP2021175759A (ja) 2021-11-04
WO2012109491A1 (en) 2012-08-16
JP2014505108A (ja) 2014-02-27
JP2016172772A (ja) 2016-09-29
AU2018201303A1 (en) 2018-03-15
CA2826765C (en) 2021-04-06
AU2022221492A1 (en) 2022-09-22
AU2021200325A1 (en) 2021-03-18
JP2020079318A (ja) 2020-05-28
RU2018129580A (ru) 2019-03-20
US20230033195A1 (en) 2023-02-02
JP2023126654A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
US20230277501A1 (en) Methods and compositions for improving cognitive function
US20230033195A1 (en) Methods and compositions for improving cognitive function
US10624875B2 (en) Methods and compositions for treating schizophrenia
US20160030391A1 (en) Methods and compositions for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
HK1261244A1 (en) Levetiracetam for improving cognitive function
HK40003608A (en) Methods and compositions for improving cognitive function
HK40021943A (en) Methods and compositions for treating schizophrenia
HK1192821A (en) Methods and compositions for improving cognitive function
AU2013344646A1 (en) Methods and compositions for treating schizophrenia